The Therapeutic Goods Administration (TGA) has issued a critical reminder regarding the use of FluMist, an intranasal influenza vaccine, emphasizing the importance of adhering to its age indications. This update comes in the wake of a concerning incident where over 80 children received the vaccine in May, despite it not being approved for their age group.
FluMist, a live attenuated influenza vaccine, is specifically recommended for children and adolescents aged between two and 17 years. The TGA's alert highlights a critical issue: adverse event reports involving FluMist in children under two years of age. These reports have been logged in the federal government's Database of Adverse Event Notifications, underscoring the potential risks associated with administering the vaccine to the wrong age group.
In May 2026, the Department of Health, Disability, and Ageing reported that 116 out of 161 FluMist-related adverse event reports involved children under two years of age. This includes 89 instances where the vaccine was administered to patients outside the recommended age range and 38 cases of incorrect product administration. While none of these events were deemed serious, the government has taken proactive measures to prevent further incidents.
Healthcare professionals are now advised to verify the age of the child before administering FluMist and to consult the TGA website for accurate product information. This precautionary step is crucial to ensure the safety and well-being of the younger population. The funding for FluMist is limited to specific age groups in different states, with Queensland and New South Wales covering children aged two to 17 years, Western Australia covering two to 12 years, and South Australia covering two to five years.
The availability of FluMist extends beyond these states, with private prescriptions covering other children in Western and South Australia, and children aged two to 17 years in Victoria, the Northern Territory, and Tasmania. However, the TGA's update serves as a stark reminder of the importance of adhering to age-appropriate vaccine guidelines.
The SNIFFLES study, conducted by the Murdoch Children’s Research Institute, offers an interesting perspective. It allows children aged two to nine years to receive FluMist instead of the standard injectable flu shot. This study provides valuable insights into the potential benefits and effectiveness of the intranasal vaccine in a specific age group. Meanwhile, the National Notifiable Disease Surveillance System has recorded a significant number of laboratory-confirmed influenza cases, with a notable proportion affecting children under five years of age.
In conclusion, the TGA's update on FluMist highlights the critical need for precise age verification when administering the vaccine. This incident serves as a reminder to healthcare professionals and parents alike to carefully follow the recommended age guidelines. As the influenza season progresses, ensuring the appropriate use of FluMist will be essential in maintaining the health and safety of the younger population.
